Información del miembro
Dr Marta Morales Ballús
España
Equipo
Dr Jaume Català Mora
España
Dr Elisa Carreras
España
Dr Itziar Alonso
España
Dr Isabel Ayet
España
Dr Ester Casas
España
Optometrist Ana Díaz
España
Dr Jesús Díaz
España
Optometrist Enric Puigventos
España
Optometrist Carles Fresno
España
Dr Carmen García Vicuña
España
Dr Hugo Gonzalez
España
Optometrist Enrique Jimenez
España
Dr Ana Llorca
España
Dr Antonio Federico Martinez Monstseny
España
Dr Joan Prat
España
Dr Gemma Romeu
España
Dr Alicia Serra
España
Optometrist Simone Suh
España
Dr Mariona Vidal
España
Optometrist Begoña Yeste
España
Dr Núria Planas
España
Centro HCP
contacte
Hospital Sant Joan de Déu, Spain
Los ensayos clínicos
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation